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Summary: Basic fibroblast growth factor (bFGF) is a polypeptide growth factor that promotes neuronal sur vival. We recently found that systemic administration of bFGF protects against both excitotoxicity and hypoxia ischemia in neonatal animals. In the present study, we examined whether systemically administered bFGF could prevent neuronal death induced by intra striatal injection of N-methyl-D-aspartate (NMDA) or chemical hypoxia induced by intrastriatal injection of malonate in adult rats and I-methyl-4-phenylpyridinium (MPP+) in neonatal rats. Systemic administration of bFGF 000 f.lg/kg) for three doses both before and after intra striatal injection of either NMDA or malonate in adult rats produced a sig-Fibroblast growth factors (FGFs) have multiple biological activities in mammalian cells (Wagner, 1991) and act as neurotrophic factors for several neuronal populations of the eNS in vitro (Walicke, 1988) and in vivo (Yamada et al., 1991) . Basic FGF (bFGF) has been shown to protect against excitato ry amino acid-induced neurotoxicity in cultured striatal and hippocampal neurons in vitro (Mattson et al., 1989; Freese et al., 1992) , and we have re ported that pretreatment with intraperitoneal ad ministration of bFGF protects against N-methyl-n aspartate (NMDA) neurotoxicity and hypoxia ischemia in neonatal rats (Nozaki et al., 1993a,b) . We have also recently shown that intraventricular nificant neuroprotective effect. In neonatal rats, bFGF produced dose-dependent significant neuroprotective ef fects against MPP + neurotoxicity, with a maximal pro tection of �50% seen with either a single dose of bFGF of 300 f.lg/kg or three doses of 100 f.lg/kg. These results show that systemic administration of bFGF is effective in pre venting neuronal injury under circumstances in which the blood-brain barrier may be compromised, raising the pos sibility that this strategy could be effective in stroke. Key Words: Basic fibroblast growth factor-Malonate-N Methy 1-D-aspartate-l-Methy 1-4-phenyl pyridinium Parkinson's disease-Stroke. administration of bFGF is neuroprotective against focal ischemia in adult rats (Koketsu et al., 1994) , which has been confirmed by another group (Morita et al., 1993) . Intraventricular administration of acidic FGF was reported to exert neuroprotective effects against ischemia-induced neuronal death in the gerbil hippocampus (Sasaki et al., 1992) .
In the present study, we examined whether intra peritoneal bFGF could exert neuroprotective ef fects against excitotoxicity produced by intrastri atal administration of NMDA in adult rats. We have also recently shown that intrastriatal administration of malonate, a reversible succinate dehydrogenase inhibitor, and I-methyl-4-phenylpyridinium (MPP + ), an inhibitor of mitochondrial complex I, results in striatal lesions sharing many features with those that accompany focal ischemia (Storey et a,l., 1992; Beal et al., 1993) . We therefore examined whether systemic administration of bFGF could at tenuate malonate neurotoxicity in adult rats or MPP + neurotoxicity in neonatal rats.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 225-250 g (Charles River, Wilmington, MA, U.S.A.) were anesthe tized with pentobarbital (50 mg/kg i.p.). NMDA and mal onate (Sigma, St. Louis, MO, U. S.A.) were dissolved in distilled deionized water and the pH was adjusted to 7.4 with 0. 1 M HCI. Intrastriatal injection of NMDA was made at a dose of 200 nmol and malonate at a dose of 3.0 ILmol in a volume of 1. 5 ILl as previously described (Beal et aI., i993) . Recombinant human bFGF was a generous gift of Creative Biomolecules (Hopkinton, MA, U.S. A.) and stored in 10 mM Tris/l mM dithiothreitollO.27 M NaCI (pH 7.4) at a concentration of 0. 55 mg/ml at -80°C. The stock solution was diluted before use in 0. 1 M phos phate-buffered saline with 100 ILg/ml of bovine serum al bumin (Boehringer Mannheim 711454) and 10 lLg/kg of heparin (Sigma 210-6). One hundred micrograms per gram of bFGF was injected intraperitoneally at 30 min prior to, at the time of injection, and at 30 min following the injec tion. Animals were killed 1 week after the intrastriatal injections.
For neonatal rat experiments, pups were removed from their mothers on the 7th day of life, kept in a temperature controlled incubator at 37.0 ± OSC for 30 min, and then briefly anesthetized with methoxyflurane (Pittman Moore, Mundelein, IL, U.S.A.). MPP+ (Research Bio chemicals, Natick, MA, U.S.A.) was dissolved in phos phate-buffered saline (pH 7.4). MPP+ (300 nmol/ 1.0 ILl) was injected into the left striatum as described previously (Nozaki et aI., 1993a) . Briefly, pups were positioned in a plaster mold of the head and body and the calvarium was exposed. Intrastriatal stereotaxic injection was done over 1 min using a Hamilton syringe with a 26-gauge needle and a microinjector. The coordinates were 0.0 mm pos terior, 2.0 mm lateral, and 3.5 ventral to the dural surface, using the bregma as a landmark. Either normal saline or bFGF at doses of 50, 100, 200, and 300 ILg/kg was admin istered 30 min before the MPP+ injection. One further group received 100 ILg/kg of bFGF at 30 min prior to and at 30 minutes and 90 min following the injection. After a 2-h recovery period, the pups were returned to their mothers for 96 h before death.
Following death by decapitation, the brains were im mediately removed and sectioned coronally into five slices at 2-mm intervals in a rodent brain matrix (Activa tional Systems, Warren, MI, U.S.A.). Slices were stained in 2% 2,3,5-triphenyltetrazolium chloride monohydrate (Sigma) solution at room temperature in the dark for 30 min followed by fixation in 4% formalin overnight. The lesion (noted by pale staining) and both hemispheres were measured on the posterior surface of each section (Bio quant IV image analysis system) by an experienced his tologist blind to the experimental conditions. At the time point of death, we found no evidence of glial proliferation using glial fibrillary acidic protein staining. The results of Nissl-stained sections show that triphenyltetrazolium chloride is a reliable marker for the lesion size. Lesion size in three malonate-injected rats was 2.68 ± 0. 11 mm2 as determined by Nissl and 2.69 ± 0. 12 mm2 for 2,3,5-tri phenyltetrazolium chloride-stained sections.
For autoradiographic studies, bFGF (145 ILg) was dis solved in 0. 2 M sodium bicarbonate buffer (pH 8. 1), mod ified with diethylenetetraminepentaacetic acid anhydride (Sigma), anhydridelbFGF = 200: 1 molar ratio. The reac tion was allowed to proceed for 20 min., and the solution J Cereb Blood Flow Metab, Vol. 15, No.4, 1995 was dialyzed overnight. I II InCl3 (3.5 mCi; DuPont Co.) in 0. 1 M sodium citrate buffer (pH 5. 3) was then added for 1 h, and nonbound I llIn was removed by gel chromatogra phy using a Sephadex G-100 column (1 x 25 cm). The specific activity of labeled protein was 22.4 ILCillLg. Neonatal (P7) Sprague-Dawley rats (n = 5) were in jected with MPP+ (300 nmoll 1.0 ILl) in the left striatum. Immediately following MPP+ injection, animals were in jected with I 1 I In-bFGF (7-8 ILg) in 0. 9% NaCI with 100 lLg/ml bovine serum albumin (50 ILl/animal). After 4 h, animals were perfusion-fixed with 4% periodate-Iysine paraformaldehyde (PLP) in 0.9% NaCl, and brains were removed and postfixed in this solution for 48 h. Brains were then cut on a vibratome at 40 ILm, and sections were mounted on poly lysine-coated slides and allowed to dry at room temperature. Sections were dehydrated in etha nol and placed on x-ray film (j3-Hypermax; Amersham) for 4 days at -80°C. Autoradiograms were developed using Kodak D-19 developer and nonhardening fixer.
To verify that the I I I In label visualized on autoradio grams remained associated with bFGF, the brain of one additional animal, prepared as described, was homoge nized in 2 M NaClIO.l M Tris-HCl, pH 7.56 (wt/vol = 1 :4), containing the protease inhibitors aprotinin, pepsta tin A, leupeptin, and trypsin inhibitor (Sigma; all at 1 ILlIml). The homogenate was centrifuged at 49,000 rpm for 1. 5 h, and the supernatant was filtered through a Millex GV filter (Millipore). The supernatant was then diluted in 0. 1 M Tris-HCl, pH 7.56 (1:1), and applied to a size ex clusion gel filtration column (BioGel P-6DG, exclusion limit 6 kDa; Biorad). The radioactivity of collected frac tions (1 ml) was determined by gamma counting. The void volume of the column was determined by application of unlabeled bovine serum albumin and analysis of collected fractions by spectrophotometry. Data are expressed as means ± SD. Statistical signifi cance of differences in lesions and hemispheric volumes between groups were determined by one-way analysis of variance followed by Fisher's protected least significant difference test.
RESULTS

Adult rat experiments
Our previous experience in neonatal rats indi cated that optimal dosing for neuroprotection against both NMDA excitotoxicity and hypoxia ischemia was achieved with a dose of 100 ,.,.g/kg of bFGF given three times both prior to and following neuronal injury. In the present experiments, we ex amined whether this regimen could exert neuropro tection against either NMDA excitotoxicity or mal onate neurotoxicity in adult rats. As shown in Fig.  1 , systemic administration of bFGF produced a sig nificant 35% reduction in lesion size resulting from intrastriatal injection of NMDA. Similarly, sys temic administration of bFGF produced a signifi cant 42% reduction in the size of the lesion pro duced by intrastriatal malonate (Fig. 2) .
Neonatal rat experiments
Initial experiments showed that a dose of 90 nmol of MPP+, which is effective in adult rats, produced no lesions. Further dose-response experiments showed that a dose of 300 nmol of MPP+ produced lesions encompassing most of the striatum. This dose of MPP + was used in further experiments to examine whether bFGF could exert neuroprotec tive effects. As shown in Fig. 3 , increasing doses of bFGF produced significant dose-dependent signifi cant neuroprotective effects against MPP+ neuro toxicity. A maximal protection of -50% was seen at a dose of 300 I-Lg/kg. Repeated dosing of 100 I-Lg/kg of bFGF at 60-min intervals provided comparable neuroprotection to that seen with a single 300-l-Lg/kg dose.
In all five neonatal brains examined by autoradi ography, labeled bFGF was visible along the needle track and throughout the parenchyma of the ipsilat eral (left) but not contralateral hemisphere (see Fig.  4 ). In one additional animal prepared in similar fash ion, the brain was removed and homogenized, and the supernatant was applied to a size exclusion gel filtration column of which the void volume had been determined previously by application of unlabeled bovine serum albumin. Approximately 67% of the radioactivity was eluted in the void volume, whereas only 33% was eluted in later column frac tions, consistent with most of the radioactivity in brain remaining associated with bFGF.
DISCUSSION
FGFs are widely distributed in the adult and neo natal CNS (Walicke, 1988) . They act as neuro trophic factors for several neuronal populations both in vitro and in vivo (Wagner, 1991; Yamada et aI., 1991) . Recent work has shown that growth fac tors are effective in several models of neuronal in- FIG. 4 . Autoradiograms of two representative neonatal rats injected with lllln-(bFGF) immediately following intrastriatal 1-methyl-4-phenylpyridinium, and killed 4 h later. There is increased uptake of lllln-bFGF in the lesioned hemisphere. jury. bFGF protects against excitatory amino acid induced neurotoxicity in cultured hippocampal and striatal neurons in vitro (Mattson et al., 1989; Freese et aI., 1992; Skaper et aI., 1993) . In addition to its effects against glutamate, bFGF is protective against Ca 2 + toxicity, hypoglycemia, NO toxicity, oxygen toxicity, and iron-induced free radicals in cultured neurons (Cheng and Mattson, 1991; Enok ido et �I., 1992; Boniece and Wagner, 1993; Maiese et aI., 1993; Mattson et aI., 1993; Zhang et aI., 1993) . Intraventricular administration of bFGF has recently been shown to be effective in models of focal ischemia in rats (Koketsu et aI., 1994) . In ad dition, immortalized fibroblasts genetically engi neered to secrete bFGF protect against excitotoxic neuronal injury in vivo (Frim et aI., 1993) .
We recently obtained the first evidence that sys temic administration of bFGF exerts neuroprotec tive effects against both NMDA excitotoxic lesions and hypoxia-ischemia in neonatal rats (Nozaki et aI., 1993a,b) . We had chosen neonatal rats since the blood-brain barrier may not be fully mature at this age, which may allow bFGF to cross into the brain. It, however, is possible that bFGF may penetrate due to breakdown of the blood-brain barrier that accompanies both excitotoxic and ischemic lesions. The present experiments suggest this is the case since labeled bFGF was found in the hemisphere adjacent to the lesions. We therefore examined whether systemic administration of bFGF might ex ert neuroprotective effects in adult rats. Systemic administration of bFGF was effective in reducing the size of lesions produced by both NMDA and malonate in adult rats. Malonate lesions are of in terest since they share many similarities with focal ischemic lesions in rats (Beal et aI., 1993) . They produce increased lactate, reduced ATP, and spar ing of medium-sized striatal aspiny neurons and they are blocked by both competitive and noncom petitive NMDA antagonists, as well as the gluta mate release inhibitor lamotrigine. Agents that are effective in focal models of ischemia in rats there fore are effective in attenuating malonate neurotox icity. This raises the possibility that systemic ad ministration of bFGF may be neuroprotective in cir cumstances in which the blood-brain barrier is compromised, such as stroke.
The finding that bFGF dose dependently blocks MPP + neurotoxicity is of interest, since this com pound is a metabolite of I-methyl-4-phenyl-l,2,3,6tetrahydropyridine, which in humans and nonhu man primates produces a model of Parkinson's dis ease. MPP + is known to inhibit complex I of the mitochondrial electron transport chain by binding at or near the rotenone binding site (Ramsey et aI., Vol. 15, No. 4, 1995 1991 . We previously showed that intrastriatal in jections of MPP + produce impaired oxidative me tabolism and striatal lesions that are attenuated by NMDA antagonists (Storey et aI., 1992) . bFGF is found in a sub popUlation of mesencephalic dopami nergic neurons, and there is a preferential depletion of these neurons in Parkinson's disease (Bean et ai. , 1991; Tooyama et aI., 1993) . bFGF exerts protec tive effects against MPP + neurotoxicity in vitro (Park and Mytilineou, 1992) , and gel implants of bFGF exert neuroprotective effects against 1methyl-4-phenyl-l,2,3,6-tetrahydropyridine neuro toxicity in mice (Otto and Unsicker, 1990) . The present results provide the first evidence that sys temic administration of bFGF can protect against MPP + neurotoxicity in vivo.
The mechanism by which bFGF exerts its neuro protective effects is presently unknown. Mattson and colleagues showed that bFGF prevents large increases in intracellular calcium produced by ei ther hypoglycemia or calcium ionophores, suggest ing improved calcium buffering or extrusion (Cheng and Mattson, 1991) . Recent studies showed that bFGF had no effect on reductions in mitochondrial transmembrane potential or reductions in ATP, de spite its ability to attenuate increased intracellular calcium and neuronal damage induced by either hy poglycemia or cyanide (Mattson et aI., 1993) .
Another mechanism by which growth factors may act is to attenuate oxidative damage. Increased intracellular calcium can contribute to free radical generation. Nerve growth factor induces catalase and protects against hydrogen peroxide-induced cell damage in vitro (Jackson et aI., 1990) . bFGF rescues neurons from cell death caused by both iron neurotoxicity and high oxygen exposure (Enokido et aI., 1992; Zhang et aI., 1993) . It is therefore of interest that both NMDA and chemical hypoxic neuronal injury have been associated with the gen eration of free radicals (LaFon-Cazel et aI., 1993) .
In summary, the present results provide the first evidence that systemic administration of bFGF is effective in attenuating excitotoxic and chemical hypoxic neuronal injury in both adult and neonatal rats. These results provide further evidence that this might be a novel therapeutic strategy for treat ment of both stroke and neurodegenerative dis eases.
